FDA Approves Lannett’s Bs-glargine IND; Biocon CY Q4 ’21 (FY Q3 ’22) Earnings Update
Two cardiometabolic-related news items have been observed: Lannett announced FDA has approved the IND application for Lannett’s bs-glargine; and Biocon hosted its Q4 ’21 (FY Q3 ’22) earnings call (press release). Below, FENIX provides highlights and insights for the respective new items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.